These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Design of HIV Coreceptor Derived Peptides That Inhibit Viral Entry at Submicromolar Concentrations. Bobyk KD; Mandadapu SR; Lohith K; Guzzo C; Bhargava A; Lusso P; Bewley CA Mol Pharm; 2017 Aug; 14(8):2681-2689. PubMed ID: 28494151 [TBL] [Abstract][Full Text] [Related]
28. Inter-retroviral fusion mediated by human immunodeficiency virus or murine leukemia virus glycoproteins: independence of cellular membranes and membrane vesicles. Sparacio S; Pfeiffer T; Holtkotte D; Bosch V Virology; 2002 Mar; 294(2):305-11. PubMed ID: 12009872 [TBL] [Abstract][Full Text] [Related]
29. Apoptotic effects in primary human umbilical vein endothelial cell cultures caused by exposure to virion-associated and cell membrane-associated HIV-1 gp120. Huang MB; Khan M; Garcia-Barrio M; Powell M; Bond VC J Acquir Immune Defic Syndr; 2001 Jul; 27(3):213-21. PubMed ID: 11464139 [TBL] [Abstract][Full Text] [Related]
30. Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity. Paterlini MG Biophys J; 2002 Dec; 83(6):3012-31. PubMed ID: 12496074 [TBL] [Abstract][Full Text] [Related]
31. Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events. Doranz BJ; Baik SS; Doms RW J Virol; 1999 Dec; 73(12):10346-58. PubMed ID: 10559353 [TBL] [Abstract][Full Text] [Related]
33. Dual Pathways of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trafficking Modulate the Selective Exclusion of Uncleaved Oligomers from Virions. Zhang S; Nguyen HT; Ding H; Wang J; Zou S; Liu L; Guha D; Gabuzda D; Ho DD; Kappes JC; Sodroski J J Virol; 2021 Jan; 95(3):. PubMed ID: 33148792 [TBL] [Abstract][Full Text] [Related]
34. Spying on HIV with SPR. Rich RL; Myszka DG Trends Microbiol; 2003 Mar; 11(3):124-33. PubMed ID: 12648944 [TBL] [Abstract][Full Text] [Related]
35. Structural and molecular interactions of CCR5 inhibitors with CCR5. Maeda K; Das D; Ogata-Aoki H; Nakata H; Miyakawa T; Tojo Y; Norman R; Takaoka Y; Ding J; Arnold GF; Arnold E; Mitsuya H J Biol Chem; 2006 May; 281(18):12688-98. PubMed ID: 16476734 [TBL] [Abstract][Full Text] [Related]
36. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. Lee B; Sharron M; Blanpain C; Doranz BJ; Vakili J; Setoh P; Berg E; Liu G; Guy HR; Durell SR; Parmentier M; Chang CN; Price K; Tsang M; Doms RW J Biol Chem; 1999 Apr; 274(14):9617-26. PubMed ID: 10092648 [TBL] [Abstract][Full Text] [Related]
37. Interactions of opioid and chemokine receptors: oligomerization of mu, kappa, and delta with CCR5 on immune cells. Suzuki S; Chuang LF; Yau P; Doi RH; Chuang RY Exp Cell Res; 2002 Nov; 280(2):192-200. PubMed ID: 12413885 [TBL] [Abstract][Full Text] [Related]
38. Human cytomegalovirus-encoded UL33 and UL78 heteromerize with host CCR5 and CXCR4 impairing their HIV coreceptor activity. Tadagaki K; Tudor D; Gbahou F; Tschische P; Waldhoer M; Bomsel M; Jockers R; Kamal M Blood; 2012 May; 119(21):4908-18. PubMed ID: 22496149 [TBL] [Abstract][Full Text] [Related]
39. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. Wu L; LaRosa G; Kassam N; Gordon CJ; Heath H; Ruffing N; Chen H; Humblias J; Samson M; Parmentier M; Moore JP; Mackay CR J Exp Med; 1997 Oct; 186(8):1373-81. PubMed ID: 9334377 [TBL] [Abstract][Full Text] [Related]
40. Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc. Latinovic O; Schneider K; Szmacinski H; Lakowicz JR; Heredia A; Redfield RR Antiviral Res; 2014 Dec; 112():80-90. PubMed ID: 25453341 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]